Stocksigma LogoStocksigma Logo

Morepen Laboratories Enters U.S. Prescription Generics Market via Wholly Owned Arm

Morepen Laboratories has launched its first prescription generic product, Desloratadine Tablets USP (5 mg), in the U.S

Morepen Laboratories Enters U.S. Prescription Generics Market via Wholly Owned Arm

Morepen Laboratories Ltd 路 Press Release 路 09 Nov 2026, 2:24 pm

Morepen Laboratories Enters U.S. Prescription Generics Market via Wholly Owned Arm Morepen Laboratories has launched its first prescription generic product, Desloratadine Tablets USP (5 mg), in the U.S. market via its wholly owned subsidiary, Morepen Bio Inc. Building on its established base as a long-standing U.S. Desloratadine API supplier, the move extends Morepen into finished-dosage formulations. Additionally, the company submitted its first ANDA to the U.S. FDA for Sitagliptin Phosphate Tablets USP (25 mg, 50 mg, and 100 mg), which is under review. Morepen plans further U.S. generic filings while evaluating high-potency APIs and oncology.

Original exchange filing (PDF)

More announcements from Morepen Laboratories Ltd

All Morepen Laboratories Ltd announcements